PDF herunterladen
J Am Acad Audiol 2000; 11(06): 323-329
DOI: 10.1055/s-0042-1748061
Case Report

Cisplatin Ototoxicity, Increased DPOAE Amplitudes, and Magnesium Deficiency

Autoren

  • Michael J. Cevette

    Mayo Clinic Scottsdale, Department of Otolaryngology, Head & Neck Surgery and Audiology, Scottsdale, Arizona

  • Danielle Drew

    Presbyterian St. Lukes Medical Center, Denver, Colorado

  • Teresa M. Webb

    Mayo Clinic Scottsdale, Department of Otolaryngology, Head & Neck Surgery and Audiology, Scottsdale, Arizona

  • Mitchell S. Marion

    Mayo Clinic Scottsdale, Department of Otolaryngology, Head & Neck Surgery and Audiology, Scottsdale, Arizona
Weitere Informationen
Auch verfügbar auf
 als PDF herunterladen Lizenzen und Reprints

Abstract

Outer hair cell (OHC) metabolism is blocked by cisplatin. Concurrent changes in the renal handling of magnesium occur because of the damage cisplatin causes to the renal proximal tubule cells within the thick ascending loop of Henle. Although there is no evidence of cisplatin within the OHCs, there are significant levels of intracellular calcium, the antagonist to magnesium at the cell membrane. The OHC motile response is dependent on intracellular calcium. When the calcium current is suppressed by an antagonist, the extracellular OHC microphonic potential decreases. Magnesium deficiency is known to produce hyperexcitabililty within the central nervous system, including fatal audiogenic seizures. In addition, increases in the amplitude of the auditory brainstem response wave V occur with aminoglycoside therapy and magnesium deficiency. This paper illustrates the amplitude growth of distortion product otoacoustic emissions in two patients treated with cisplatin and explores the possible underlying reasons why this may be related to magnesium metabolism.

Abbreviations: DPOAEs = distortion product otoacoustic emissions, OAEs = otoacoustic emissions, OHC = outer hair cell, TEOAEs = transient otoacoustic emissions

Key Words

Cisplatin chemotherapy - distortion product otoacoustic emissions - magnesium deficiency - outer hair cells - transient evoked otoacoustic emissions


Publikationsverlauf

Artikel online veröffentlicht:
08. April 2022

© 2000. American Academy of Audiology. This article is published by Thieme.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • REFERENCES

  • Aguilar-Markulis NV, Beckley S, Priore R, Mettlin C. (1981). Auditory toxicity effects of long-term cis-dichlor-diammineplatinum (II) therapy in genitorurinary cancer patients. J Surg Oncol 16:111–123.
  • al-Ghamdi SM, Cameron EC, Sutton RA. (1995). Magnesium deficiency: pathophysiologic and clinical overview. Am J Kidney Dis 24:737–752.
  • Ashmore JF, Meech RW. (1986). Ionic basis of membrane potential in outer hair cells of guinea pig cochlea. Nature 322:368–371.
  • Attias J, Weisz G, Shlomo A, Shahar A, Wiener M, Joachims A, Netzer A, Ising H, Rebentisch E, Guenther Τ. (1994). Oral magnesium intake reduces permanent hearing loss induced by noise exposure. Am J Otolarynogol 15(l):26–32.
  • Bac P, Pages N, Herrenknecht C, Dewulf C, Binet P, Durlach J. (1994). Effect of various serotoninergically induced manipulations on audiogenic seizures in magnesium-deficient mice. Magnes Res 7:107–115.
  • Bobbin RP, Jastreboff PJ, Fallon M, Littman T. (1990). Nimodipine, an L-channel Ca2+ antagonist, reverses the negative summating potential recorded from the guinea pig cochlear. Hear Res 46:277–288.
  • Bonfils P, Bertrand Y, Uziel A. (1988). Evoked otoacoustic emissions: normative data and presbycusis. Audiology 27:27–35.
  • Brown DR, Feldman AM. (1978). Pharmacology of hearing and ototoxicity. Ann Rev Pharmacol Toxicol 18:233–252.
  • Brownell WE. (1990). Outer hair cell electomotility and otoacoustic emissions. Ear Hear 11:82–92.
  • Brusilow SW, Gordes E. (1973). The mutual independence of the endolymphatic potential and the concentrations of sodium and potassium in the endolymph. J Clin Invest 52:2517–2521.
  • Cevette MJ, Franz KB, Brey RH, Robinette MS. (1989). Influence of dietary magnesium on the amplitude of the wave V of the auditory brainstem response. Otolaryngol Head Neck Surg 101:537–541.
  • Cheung NY, Bonventre JV, Malis CD, Leaf A. (1986). Calcium and ischemic injury. Ν Engl J Med 314–1670–1676.
  • Chutkow JG. (1980). The neurophysiologic function of magnesium: effects of magnesium excess and deficit. In: Cantin M, Seelig MS, eds. Magnesium in Health and Disease. New York: Spectrum, 713–752.
  • Chutkow JG, Grawbow JD. (1972). Clinical and chemical correlations in magnesium-deprivation encephalopathy of young rats. Am J Physiol 223:1407–1414.
  • Comis SD, Rhys-Evans PH, Osborne MP, Pickles JO, Jeffries DJ, Pearse HA. (1986). Early morphological and chemical changes induced by cisplatin in the guinea pig organ of Corti. J Laryngol Otol 100:1375–1383.
  • Dallos P. (1988). Cochlear neurobiology: revolutionary developments. ASHA 30(6–7):50–56.
  • Daugaard G, Abildgaard U, Holstein-Rathlou NH, Bruunshuus I, Bucher D, Leyssac PP. (1988). Renal tubular function in patients treated with high-dose cisplatin. Clin Pharmacol Ther 44:164–172.
  • Dickerson RN, Brown RO. (1985). Hypomagnesemia in hospitialized patients receiving nutritional support. Heart Lung 14:561–567.
  • Fausti SA, Schechter MA, Rappaport BZ, Frey RH, Mass RE. (1984). Early detection of cisplatin ototoxicity. Selected case reports. Cancer 53:224–231.
  • Feldman AM, Brusilow SW. (1976). Effects of cholera toxin on cochlear endolymph productions: model for endo-cochlear hydrops. Proc Nat Acad Sci USA 73:1761–1764.
  • Franklin DJ, McCoy MJ, Martin GK, Lonsbury-Martin BL. (1992). Test retest reliability of distortion-product and transiently evoked otoacoustic emissions. Ear Hear 13:417–429.
  • Furst G, Maurer J, Schlegel J. (1995). Monitoring ototoxic side effects in streptomycin therapy of tuberculosis patients with transitory evoked otoacoustic emissions TEOAE. Pneumologie 49:590–595.
  • Joachims Z, Babisch W, Ising H, Gunther Τ, Handrock Μ. (1983). Dependence of noise-induced hearing loss upon perilymph magnesium concentration. J Acoust Soc Am 74:104–108.
  • Kakigi A, Hirakawa H, Harel N, Mount RJ, Harrison RV. (1998). Basal cochlear lesions result in increased amplitude of otoacoustic emissions. Audiol Neurootol 3:361–372.
  • Kemp DT. (1978). Stimulater acoustic emission from within the human auditory system. J Acoust Soc Am 64:1386–1391.
  • Kemp DT, Bray P, Alexander L, Brown AM. (1986). Acoustic emission cochleography: practical aspects. Scarid Audiol Suppl 25:71– 95.
  • Klein AJ, Armstrong BL, Greer MK, Brown FR III. (1990). Hyperacusis and otitis media in individuals with Williams syndrome. J Speech Hear Disord 55:339–344.
  • Kujawa SG, Fallon M, Bobhin RR (1992). Intracochlear salicylate reduces low-intensity acoustic and cochlear microphonic distortion products. Hear Res 64:73–80.
  • Lam M, Adelstein DJ. (1986). Hypomagnesemia and renal magnesium wasting in patients treated with cisplatin. Am J Kidney Dis 8:164–169.
  • McAlpine D, Johnstone BM. (1990). The ototoxic mechanism of cisplatin. Hear Res 47:191–203.
  • Nakagawa T, Kakehata S, Akaike N, Komune S, Takasaka T, Uemura T. (1992). Effects of Ca2+ antagonists and aminoglycoside antibiotics on Ca2+ current in isolated outer hair cells of guinea pig cochlea. Brain Res 580: 345–347.
  • Plinkert PK, Krober S. (1991). Early detection of cisplatin-induced ototoxicity using evoked otoacoustic emissions. Laryngol Rhinol Otol 70:457–462.
  • Probst R, Lonsbury-Martin BL, Martin GK, Coats AC. (1987). Otoacoustic emissions in ears with hearing loss. Am J Otolaryngol 8:73–81.
  • Probst R, Harris FP, Hauser R. (1993). Clinical monitoring using otoacoustic emissions. Br J Audiol 27:85–90.
  • Raveh E, Mount RJ, Harrison RV. (1998). Increased otoacoustic-emission amplitude secondary to cochlear lesions. J Otolaryngol 27:354–360.
  • Reddel RR, Kefford RF, Grant JM, Coates AS, Fox RM, Tattersall MH. (1982). Ototoxicity in patients receiving cisplatin: importance of dose and method of drug administration. Cancer Treat Rep 66:19–23.
  • Roede J, Harris FP, Probst R, Xu L. (1993). Repeatability of distortion product otoacoustic emissions in normally hearing humans. Audiology 32:273–281.
  • Saito R, Aran J. (1994). X-ray microanalysis and ion microscopy of guinea pig cochlear and kidney after cisplatin treatment. ORL J Otorhinolaryngol Relat Spec 56:310–314.
  • Seelig JM. (1994). Consequences of magnesium deficiency on the enhancements of stress reactions: preventative and therapeutic implications. J Am Coll Nutr 13:429–446.
  • Seelig MS. (1981). Magnesium requirements in human nutrition. Magnes Bull 3:26–47.
  • Sweetow RW, Will TI. (1993). Progression of hearing loss following completion of chemotherapy and radiation therapy: case report. J Am Acad Audiol 4:360–363.
  • Trump BF, Berezesky IK, Sato T, Laiho KU, Phelps PC, DeClaris N. (1984). Cell calcium, cell injury, and cell death. Environ Health Perspect 57:281–287.
  • Waters GS, Ahmad M, Katsarkas A, Stanimir G, McKay J. (1991). Ototoxicity due to cis-diamminedichloroplatinum in the treatment of ovarian cancer: influence of dosage and schedule of administration. Ear Hear 12:91–102.
  • Whitehead ML, Lonsbury-Martin BL, Martin GK. (1992). Relevance of animal models to the clinical application of otoacoustic emissions. Semin Hear 13:81–101.